Do two current canine parvovirus type 2 and 2b vaccines provide protection against the new type 2c variant?

Veterinary Therapeutics

Volumn 9, Issue 2, 2008, Pages 94-101

  Larson, Laurie J ^a   Schultz, R D ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS ANTIBODY; VIRUS VACCINE;

ANIMAL; ANIMAL DISEASE; ARTICLE; BIOSYNTHESIS; BLOOD; CLASSIFICATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOG; DOG DISEASE; FECES; FELINE PANLEUKOPENIA VIRUS; FEMALE; IMMUNOLOGY; MALE; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; SEROTYPING; TREATMENT OUTCOME; VACCINATION; VIROLOGY; VIRUS INFECTION; VIRUS SHEDDING;

ANIMALS; ANTIBODIES, VIRAL; DOG DISEASES; DOGS; FECES; FEMALE; MALE; PARVOVIRIDAE INFECTIONS; PARVOVIRUS, CANINE; SEROTYPING; TREATMENT OUTCOME; VACCINATION; VIRAL VACCINES; VIRUS SHEDDING;

ANIMALIA; CANINE PARVOVIRUS 2; CERCOPITHECINE HERPESVIRUS 1; FELINE PANLEUKOPENIA VIRUS;

EID: 48049122436     PISSN: 15283593     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Eugster AK, Bendele RA, Jones LP. Parvovirus infection in dogs. JAVMA 1978;173:1340-1341.
2. Appel MJG, Scott FW, Carmichael LE. Isolation and immunization studies of a canine parvo-like virus from puppies with haemorrhagic enteritis. Vet Rec 1979;105:156-159.
3. Carmichael LE. Canine parvovirus type-2. an evolving pathogen of puppies. Ann Vet Med 1994;135:459-464.
4. Carmichael LE. An annotated historical account of canine parvovirus. J Vet Med B Infect Dis Vet Public Health 2005;52(7-8):303-311.
5. Parrish CR, Aquadro CF, Strassheim ML, et al. Rapid antigenic-type replacement and DNA sequence evolution of canine parvovirus. J Virol 1991;65(12):6544-6552.
6. Truyen U, Evermann JF, Vieler E, Parrish CR. Evolution of canine parvovirus involved loss and gain of feline host range. Virology 1996;215:186-189.
7. Shackelton LA, Parrish CR, Truyen U, Holmes EC. High rate of viral evolution associated with the emergence of carnivore parvovirus. Proc Natl Acad Sci USA 2005;102:379-384.
8. Buonavoglia C, Martella V, Pratelli A, et al. Evidence for evolution of canine parvovirus type 2 in Italy. J Gen Virol 2001;82:3021-3025.
9. Martella V, Decaro N, Elia G, Buonavoglia C. Evolution of CPV-2 and implication for antigenic/genetic characterization. Virus Genes 2006;33:11-13.
10. Olsen LB, Larson LJ, Schultz RD. Canine parvovirus (CPV-2b) infection in cats [abstract P167]. Proc 78th Meet Conf Res Work Anim Dis, 1998.
11. Truyen U. Evolution of canine parvovirus: a need for new vaccines? Vet Microbiol 2006;117:9-13.
12. Martella V, Cavalli A, Pratelli A, et al. A canine parvovirus mutant is spreading in Italy. J Clin Microbiol 2004;42:1333-1336.
13. Larson LJ, Schultz RD. Comparison of selected canine vaccines for their ability to induce protective immunity against canine parvovirus infection. Am J Vet Res 1997;58:360-363.
14. Carmichael LE, Joubert JC, Pollock RV. Hemagglutination by canine parvovirus: serologic studies and diagnostic applications. Am J Vet Res 1980;41:784-791.
15. Bass EP, Gill MA, Beckenhauer WH. Development of a modified live, canine origin parvovirus vaccine. JAVMA 1982;181:909-913.
16. Schultz RD. Considerations in designing effective and safe vaccination programs for puppies. In: Carmichael LE, ed. Recent Advances in Canine Infectious Diseases. International Veterinary Information Service; 2000. Document number A0110.0500. Accessed May 2008 at vcww.ivis.org.
17. Schultz RD. Duration of immunity for canine and feline vaccines: a review. Vet Microbiol 2006;117(1):75-79.
18. Abdelmagid OY, Larson L, Payne L, et al. Evaluation of the efficacy and duration of immunity of a canine combination vaccine against virulent parvovirus, infectious canine hepatitis virus, and distemper virus experimental challenges. Vet Ther 2004;5(3):173-186.
19. Schuhz RD, Conklin S. Serologic (antibody) analysis is an excellent indicator for "immunologic memory" following vaccination for any disease and specific indication of protective immunity for certain diseases. the immune system and vaccine challenges for the 21st century. Compend Contin Educ Pract Vet 1998; 20(Suppl 8C):5-18.
20. Pereira CA, Leal ES, Durigon EL. Selective regimen shift and demographic growth increase associated with the emergence of high-fitness variants of canine parvovirus. Infect Genet Evol 2007;7(3):399-409.
21. Carmichael LE. Canine viral vaccines at a turning point - a personal perspective. In: Schultz RD, ed. Advances in Veterinary Medicine 41: Veterinary Vaccines and Diagnostics. San Diego: Veterinary Academic Press; 1999;289-307.
22. Yule TD, Roth MB, Dreier K, et al. Canine parvovirus vaccine elicits protection from the inflammatory and clinical consequences of the disease. Vaccine 1997;15: 720-729.
23. Greenwood NM, Chalmers WS, Baxendale W, Thompson H. Comparison of isolates of canine parvovirus by restriction enzyme analysis, and vaccine efficacy against field strains. Vet Rec 1995;136(3):63-67.